(2- (4- methoxyphenyl)- 4- quinolinyl)(2- piperidinyl)methanol

04/01/2015 - "The purpose of this study was to evaluate the effects of NSC23925 on the prevention of MDR in ovarian cancer, especially in vivo. "
04/01/2015 - "Our findings suggest that NSC23925 can prevent the emergence of MDR in ovarian cancer both in vitro and in vivo. "
04/01/2015 - "NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo."
10/15/2015 - "The aim of our study is to determine the effects of NSC23925 on preventing the development of paclitaxel resistance in ovarian cancer both in cultured cells in vitro and in mouse xenograft models in vivo, and to further elucidate these underlying mechanisms. "
10/15/2015 - "Collectively, our observations provide evidence that NSC23925 in combination with paclitaxel may prevent the onset of Pgp or antiapoptotic-mediated paclitaxel resistance, and improve the long-term clinical outcome in patients with ovarian cancer. "

06/10/2014 - "However, whether NSC23925 can prevent the development of MDR in cancer is unknown. "
10/12/2009 - "The cytotoxic activity of NSC23925 was further evaluated using a panel of cancer cell lines expressing Pgp1, MRP, and BCRP. "
10/12/2009 - "The ability of NSC23925 to restore sensitivity to the cytotoxic effects of chemotherapy or to prevent resistance could significantly benefit cancer patients."
06/10/2014 - "Given the significant incidence of MDR in osteosarcoma and the lack of effective agents for prevention of MDR, NSC23925 and derivatives hold the potential to improve the outcome of cancer patients with poor prognosis due to drug resistance."
04/12/2012 - "Prior studies have identified (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (5) (NSC23925) to be a small molecule agent that reverses MDR in cancer cells. "

06/10/2014 - "Therefore, this study aims to evaluate the effects of NSC23925 on prevention of the development of MDR in osteosarcoma. "
04/01/2015 - "NSC23925 previously has been shown to prevent the development of MDR in osteosarcoma cells in vitro. "
06/10/2014 - "Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925."
06/10/2014 - "Given the significant incidence of MDR in osteosarcoma and the lack of effective agents for prevention of MDR, NSC23925 and derivatives hold the potential to improve the outcome of cancer patients with poor prognosis due to drug resistance."
06/10/2014 - "Human osteosarcoma cell lines U-2OS and Saos were exposed to increasing concentrations of paclitaxel alone or in combination with NSC23925 for 6 months. "

10/15/2015 - "Furthermore, the combination of paclitaxel and NSC23925 therapy did not induce obvious toxicity as measured by mice body weight changes, blood cell counts and histology of internal organs. "